The Trump administration has withdrawn White House aide Heidi Overton’s nomination to lead the US Food and Drug Administration.
PHOTO: AP

White House pulls FDA chief nominee Heidi Overton before hearing

· The Straits Times
  • The White House has withdrawn Heidi Overton’s FDA chief nomination before a Senate hearing, citing weak congressional support, Axios reported.
  • Critics from both parties questioned her record on vaccines, pesticides, food policy, mifepristone and fruit-flavoured vapes, deepening the row.
  • The move leaves the FDA without a permanent commissioner and adds to turmoil, with Kyle Diamantas acting temporarily and a possible Senate deadline in January.

WASHINGTON – The Trump administration has withdrawn White House aide Heidi Overton’s nomination to lead the US Food and Drug Administration (FDA), according to people familiar with the matter, leaving the agency without a permanent commissioner as the political path to filling the post grows more complicated.

The Senate Health, Education, Labour and Pensions committee was slated to vote on Nov 18 whether to recommend Overton for a full floor vote.

The White House has dropped the bid due to lack of congressional support, according to Axios, which had reported the news earlier on Nov 17.

A White House spokesperson and Overton didn’t immediately respond to requests for comment.

Overton was the target of criticism from Calley Means, who recently left his job as one of Health Secretary Robert F. Kennedy Jr’s top advisers.

In a scorched-earth campaign following his departure, Means claimed Overton opposed Kennedy’s policy goals on pesticides, food policy, vaccines and psychedelic treatments.

The fate of Overton’s nomination was unclear even before Means’ attacks.

Senator Bill Cassidy, a Louisiana Republican who leads the Senate HELP committee, criticised Overton for helping craft President Donald Trump’s executive order proposing an overhaul of childhood vaccinations.

Maine Republican Senator Susan Collins said she had concerns about the FDA’s authorisation of fruit-flavoured vapes earlier in 2026 and Alaska Senator Lisa Murkowski expressed concerns about the agency’s approach to the abortion pill mifepristone. 

The withdrawal will extend a period of turmoil at the FDA, which regulates products that account for roughly a fifth of consumer spending in the US.

Former Commissioner Marty Makary resigned in May after 13 months in the top role that were marred by clashes with staff and pushback from biotech companies.

Soon after, a wave of other senior leaders departed. 

It’s unclear whether the White House will be able to advance a nominee before Democrats take control of the Senate in January.

Attorney Kyle Diamantas, who previously headed the agency’s food centre, is leading the FDA on a temporary basis. 

Diamantas plans to depart the agency by the end of the year, according to people familiar with the matter who were not authorised to discuss personnel matters publicly.

The Trump administration has had several high-profile failed nominations for top health positions, including two for surgeon general and one to lead the Centres for Disease Control and Prevention.

The surgeon general role remains unfilled; Erica Schwartz took the helm at CDC in August.

Overton is a deputy assistant to the president for domestic policy, focused on health issues.

She worked at the think tank America First Policy Institute, is a medical doctor and has a doctorate in clinical investigation from Johns Hopkins University.

She was also a White House fellow in the first Trump administration. BLOOMBERG